Summarized by Masters of Longevity from Longevity Technology.
News that a small RNA company licensed an ALK7-targeting RNAi obesity candidate to a major pharma, outlining the deal and potential adipose-focused mechanism.
Key Takeaways
- Rona Therapeutics granted Roche an exclusive worldwide license to its ALK7-silencing RNAi candidate.
- Rona can receive $100 million upfront and near-term payments plus up to $1.06 billion in later milestones.
- No human clinical data or development timeline were disclosed in the announcement.
